Design and evaluation of new unified criteria for disseminated intravascular coagulation based on the Japanese Association for acute medicine criteria

Clinical and Applied Thrombosis/Hemostasis

Volumn 22, Issue 2, 2016, Pages 153-160

  Umemura, Yutaka ^a   Yamakawa, Kazuma ^b   Kiguchi, Takeyuki ^a   Yoshikawa, Yoshiaki ^a   Ogura, Hiroshi ^b   Shimazu, Takeshi ^b   Hamasaki, Toshimitsu ^b   Fujimi, Satoshi ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

biological markers; diagnosis; disseminated intravascular coagulation; sepsis; standards

Indexed keywords

MOLECULAR MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; BIOLOGICAL MARKER; SERPINE1 PROTEIN, HUMAN;

ADULT; AGED; APACHE; AREA UNDER THE CURVE; ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HOSPITAL ADMISSION; HUMAN; JAPAN; JAPANESE ASSOCIATION FOR ACUTE MEDICINE DIC CRITERIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TERTIARY CARE CENTER; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISSEMINATED INTRAVASCULAR COAGULATION; FOLLOW UP; METABOLISM; MIDDLE AGED; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL RATE;

AGED; BIOMARKERS; DISEASE-FREE SURVIVAL; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PROTEIN C; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 84957636356     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029615591169     Document Type: Article

References (29)

1. Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA. 2001; 286 (15): 1869-1878.
2. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344 (10): 699-709.
3. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290 (2): 238-247.
4. Polderman KH, Girbes AR,. Drug intervention trials in sepsis: divergent results. Lancet. 2004; 363 (9422): 1721-1723.
5. Gando S,. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010; 38 (2 suppl): S35-S42.
6. Aoki N, Hasegawa H,. About revised version of 'Auxiliary test findings and results for diagnostic' in diagnostic criteria for DIC: a study report by the research committee on blood coagulation on abnormalities in 1987. Special diseases designated by Japanese Ministry of Health and Welfare. 1988; 37-41.
7. Gando S, Wada H, Asakura H, et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost. 2005; 11 (1): 71-76.
8. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86 (5): 1327-1330.
9. Wada H, Minamikawa K, Wakita Y, et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol. 1993; 43 (3): 190-194.
10. Wada H, Mori Y, Shimura M, et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol. 1998; 58 (3): 189-194.
11. Habe K, Wada H, Ito-Habe N, et al. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res. 2012; 129 (5): 598-602.
12. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 1996; 22 (7): 707-710.
13. Iba T, Gando S, Murata A, et al.Japanese Association for Acute Medicine Disseminated Intravascular Coagulation Study Group. Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma. 2007; 63 (5): 1093-1098.
14. Kiguchi T, Nakamori Y, Yamakawa K, et al. Maximal chemiluminescent intensity in response to lipopolysaccharide assessed by endotoxin activity assay on admission day predicts mortality in patients with sepsis. Crit Care Med. 2013; 41 (6): 1443-1449.
15. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101 (6): 1644-1655.
16. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008; 34 (1): 17-60.
17. Levy MM, Fink MP, Marshall JC, et al. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31 (4): 1250-1256.
18. Gando S, Iba T, Eguchi Y, et al.Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006; 34 (3): 625-631.
19. Gando S, Saitoh D, Ogura H, et al.Japanese Association for Acute Medicine Sepsis Registry Study Group. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care. 2013; 17 (3): R111.
20. Bewick V, Cheek L, Ball J,. Statistics review 13: receiver operating characteristic curves. Crit Care. 2004; 8 (6): 508-512.
21. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44 (3): 837-845.
22. Shapiro NI, Schuetz P, Yano K, et al. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care. 2010; 14 (5): R182.
23. Conway EM, Rosenberg RD,. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol. 1988; 8 (12): 5588-5592.
24. Wada H, Hatada T, Okamoto K, et al. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol. 2010; 85 (9): 691-694.
25. Lee JH, Song J,. Diagnosis of non-overt disseminated intravascular coagulation made according to the International Society on Thrombosis and Hemostasis criteria with some modifications. Korean J Hematol. 2010; 45 (4): 260-263.
26. Takemitsu T, Wada H, Hatada T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost. 2011; 105 (1): 40-44.
27. Madách K, Aladzsity I, Szilágyi A, et al. 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Crit Care. 2010; 14 (2): R79.
28. Semeraro N, Ammollo CT, Semeraro F, Colucci M,. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr J Hematol Infect Dis. 2010; 2 (3): e2010024.
29. Wada H, Wakita Y, Nakase T, et al.Mie DIC Study Group. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost. 1995; 74 (3): 848-852.